A service of the U.S.

National Library of Medicine

My NCBI
and the National Institutes of Health
[Sign In] [Register]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Advanced Search
Search PubMed for Go
Clear
Limits Preview/Index History Clipboard Details

Display AbstractPlus Show 20 Sort By Send to

All: 1 Review: 0

1: Med Hypotheses. 1991 Nov;36(3):185-9. Links

Innovation vs. quality control: an 'unpublishable' clinical trial of supplemental ascorbate in incurable Related Articles
cancer.
Prolongation of survival times of terminal cancer patients by administration of
large doses of ascorbate. [ Int J Vitam Nutr Res Suppl. 1982]
Cameron E, Campbell A.
Supplemental ascorbate in the supportive treatment of cancer: reevaluation of
Vale of Leven Hospital, Alexandria, Scotland, UK. prolongation of survival times in terminal human cancer.
[P roc Natl Acad Sci U SA. 1978]

A computerized data bank was created recording the details of all cancer patients attending three district Supplemental ascorbate in the supportive treatment of cancer: Prolongation of
survival times in terminal human cancer. [P roc Natl Acad Sci U SA. 1976]
general hospitals in West Central Scotland over a 4.5 year period 1978-1982. At the conclusion of the trial, the
records of 2804 individual patients were available for study, of whom 1826 had reached an incurable stage. 294 of Review A rapid and systematic review of the clinical effectiveness and
these incurable cancer patients had received supplemental ascorbate at some stage in their illness, whereas cost-effectiveness of topotecan for ovarian cancer. [H ea lth Technol Assess. 2001]
1532 had not, and served as controls. Analysis showed that the ascorbate-supplemented patients had a median Review Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes
overall survival time (343 days) almost double that of the controls (180 days). Our difficulties in having this mellitus. [Pharmaco economics. 2004]
simple, but important, observation published are briefly recounted in the introduction.
» See Reviews... | » See All...
PMID: 1787807 [PubMed - indexed for MEDLINE]

Patient Drug Information

Ascorbic Acid (Cecon® Drops, Cenolate® , Cevi-Bid® , ...) Ascorbic acid is used
to prevent and treat scurvy, a disease caused by a lack of vitamin C in the body.

Source: AHFS Consumer Medication Information

Recent Activity

Turn Off Clear

Innovation vs. quality control: an 'unpublishable' clinical trial of supplemental

ascorbat...

Indomethacin and ascorbate inhibit desmoid tumors.

Inhibition of benzo(a)pyrene carcinogenesis in rats with vitamin C.

Preventive action of vitamin C on nitrosamine formation.

Prolongation of survival times of terminal cancer patients by administration

of large dose...

Display AbstractPlus Show 20 Sort By Send to

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer